Rodriguez-Freixinos V, et al. - In heavily pretreated (≥3 CT lines) germline(g)/somatic(s) BRCA1/2 mutation ovarian cancer (BMOC) patients, researchers tested the effectiveness of chemotherapy. They calculated overall survival (OS) and time to progression (TTP) in g/sBMOC patients who received CT from 2006 to 2016 at 4 cancer centers in Spain. They identified 135 g/sBMOC patients (6% sBRCA1/2 mutations). The median number of chemotherapy lines was 2 (1–7). The rates of 6-years OS in BRCA1 or BRCA2 mutation carriers were 69.4% and 71%, respectively. They noted, ≥3 CT lines (3–7), which encompassed a total of 155 treatments, were received by 57 (42%) patients. They observed that, the median overall TTP across all treatment lines beyond 2nd line was 10.2 months. Findings showed CT sensitivity in heavily pretreated g/sBMOC, including for non-platinum-based chemotherapy (PCT) choices. In heavily pretreated g/sBMOC patients, improved prognosis was observed in association with primary platinum-free interval (PFI) >12 months and exposure to both platinum-based chemotherapy and PARP inhibitors (PARPi).